{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:57:01Z","timestamp":1790542621304,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100287","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:29:10Z","timestamp":1786638550000},"page":"100287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse\/refractory T-cell lymphoma"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-4451","authenticated-orcid":false,"given":"Max J.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos D.","family":"Miljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Lakhotia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-4570","authenticated-orcid":false,"given":"Christopher","family":"Melani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-4226","authenticated-orcid":false,"given":"Jagan","family":"Muppidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0076-0224","authenticated-orcid":false,"given":"Irini","family":"Sereti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Staudt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bneo.2026.100287_bib1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.2025030149","article-title":"Early time to relapse as a survival prognosticator in mature T-cell\/NK-cell lymphomas: results from the PETAL Consortium","volume":"147","author":"Sorial","year":"2026","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2026.100287_bib2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.3324\/haematol.2023.282716","article-title":"Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions","volume":"108","author":"Bisig","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.bneo.2026.100287_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003388","article-title":"Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors","volume":"9","author":"Conlon","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2026.100287_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100054","article-title":"A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies","volume":"2","author":"Gordon","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"3","key":"10.1016\/j.bneo.2026.100287_bib5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/bloodadvances.2021006440","article-title":"Interleukin-15 augments NK-cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies","volume":"7","author":"Miljkovic","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bneo.2026.100287_bib6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/10428194.2024.2326847","article-title":"A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma","volume":"65","author":"Gordon","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.bneo.2026.100287_bib7","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bneo.2026.100287_bib8","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100287_bib9","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","volume":"11","author":"Dupuis","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100287_bib10","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2025019186","article-title":"A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphoma","volume":"10","author":"Gordon","year":"2026","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100287_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood-2023-190213","article-title":"Post-allograft romidepsin maintenance mitigates relapse risk and stimulates the graft-versus-malignancy effect through enhanced NK-cell cytotoxicity in patients with T-cell malignancies: final results of a phase I\/II trial","volume":"142","author":"Hosing","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100287_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100287_bib13","article-title":"Decitabine promotes the differentiation of poorly differentiated gastric cancer cells and enhances the sensitivity of NK-cell cytotoxicity via TNF-\u03b1","volume":"15","author":"Lv","year":"2025","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.bneo.2026.100287_bib14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bneo.2026.100287_bib15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/his.14670","article-title":"CD70 is a potential target biomarker in peripheral T-cell lymphomas","volume":"81","author":"Marques-Piubelli","year":"2022","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.bneo.2026.100287_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100287_bib17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cyto.a.24213","article-title":"OMIP-069: forty-color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood","volume":"97","author":"Park","year":"2020","journal-title":"Cytometry A"},{"issue":"3_Supplement","key":"10.1016\/j.bneo.2026.100287_bib18","doi-asserted-by":"crossref","first-page":"A046-A","DOI":"10.1158\/2643-3249.LYMPHOMA26-A046","article-title":"Abstract A046: Dynamic changes in peripheral blood immune cells are associated with response to targeted therapies in relapsed\/refractory T-cell lymphoma","volume":"7","author":"Ozcan","year":"2026","journal-title":"Blood Cancer Discovery"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:07:55Z","timestamp":1790539675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026000981"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100287","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse\/refractory T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100287"}}